SERVIER UKRAINE

Servier Ukraine LLC is an international and independent pharmaceutical company governed by a non-profit foundation, with headquarters in Suresnes, France. Since opening our first laboratory in 1954, we have been committed to therapeutic progress to serve patient needs with the help of healthcare professionals. We strive to provide future generations with a world where quality healthcare is available and accessible to all.
Operating in 148 countries, we have 21,600 collaborators employed worldwide and a turnover of 4.152 billion euros in 2017. Entirely independent, we are able to reinvest 25% of our total revenue (excluding generics) into Research and Development, and all profits are used for further development.
Corporate growth at Servier is driven by our continuous pursuit of innovation in five areas of excellence: cardiovascular and immune-inflammatory diseases, neuropsychiatric disorders, cancer and diabetes. We are a leading force in cardiology—number 2 in Europe, number 8 worldwide—and oncology has become a top priority in recent years; we also manufacture high-quality generic drugs.
Our three research centres are continuously involved in creating, testing, and developing new medicinal products, which are manufactured and packaged in our 16 production centres around the world. We have an active partnership policy in the field of biotechnology and we are investing in e-health through our internal WeHealth by Servier initiative.
All our employees are driven by shared values and guided by a common vision. Together we share the passion of
entrepreneurship and we are committed to therapeutic progress to serve patient needs.

Please note!
Collaboration of companies with shared values is main goal of this project.
We will read your message and redirect it to a company's employee whom it can be as useful as possible.
Your company has 5 opportunities per year to get acquainted with other companies. If you want to increase this amount, please contact us
Please note, that according to EBA Code of Conduct it is prohibited to perform on the EBA platform any coordinated actions, which may limit the competition between the EBA Members.
Write us in case of additional questions and suggestions.

Spelling error report

The following text will be sent to our editors: